Last 48 quarters of trend data · Healthcare · Specialty & Generic Drugs
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 7.12 | — | — | 2.62 | 2.58 | 4.22 | 6.52 | — | 18.07 | 250.13 | — | 8.28 | 5.28 | 3.31 | 159.13 | 6.70 | — | 1.04 | 369.00 | 24.19 | 30.80 |
| — | — | — | — | -85.7% | -98.3% | — | — | +242.5% | +7448.2% | — | +23.7% | — | +219.7% | -56.9% | -72.3% | — | -77.7% | +9806.0% | +580.1% | +377.3% | |
| P/S Ratio | 3.19 | 3.60 | 3.49 | 5.04 | 3.61 | 3.60 | 4.23 | 3.21 | 3.98 | 3.40 | 2.48 | 4.16 | 3.97 | 4.16 | 2.57 | 3.31 | 3.51 | 4.14 | 3.26 | 5.03 | 3.27 |
| — | +0.1% | -17.6% | +57.3% | -9.3% | +5.9% | +70.5% | -22.8% | +0.2% | -18.4% | -3.6% | +25.7% | +13.2% | +0.6% | -21.1% | -34.3% | +7.1% | +18.6% | -2.6% | +26.8% | -15.8% | |
| P/B Ratio | 1.38 | 1.34 | 1.35 | 1.47 | 1.45 | 1.54 | 2.37 | 1.76 | 2.11 | 1.82 | 1.54 | 1.83 | 2.02 | 1.78 | 1.50 | 1.80 | 1.63 | 1.73 | 2.50 | 3.28 | 2.68 |
| — | -12.5% | -43.0% | -16.2% | -31.2% | -15.6% | +54.0% | -4.0% | +4.6% | +1.9% | +2.6% | +1.8% | +23.8% | +2.8% | -39.8% | -45.2% | -39.2% | -37.5% | -27.2% | +68.5% | +15.8% | |
| P/FCF | 7.77 | 9.17 | 8.09 | 14.21 | 7.98 | 7.98 | 9.62 | 5.85 | 6.61 | 6.28 | 5.86 | 8.69 | 10.30 | 6.40 | 5.46 | 9.84 | 26.03 | 17.74 | 4.47 | 4.62 | 4.63 |
| — | +15.0% | -16.0% | +143.0% | +20.7% | +27.1% | +64.1% | -32.8% | -35.8% | -1.9% | +7.4% | -11.7% | -60.4% | -63.9% | +22.2% | +113.0% | +461.7% | +402.7% | +12.0% | +14.5% | +12.3% | |
| EV / EBITDA | 5.35 | 5.81 | 5.60 | 8.85 | 7.24 | 8.48 | — | — | 8.09 | 5.88 | 5.15 | 12.09 | 9.19 | 11.25 | 11.81 | 13.17 | 8.41 | 24.69 | 4.85 | 11.21 | 3.71 |
| — | -31.5% | — | — | -10.5% | +44.1% | — | — | -12.0% | -47.7% | -56.4% | -8.2% | +9.2% | -54.4% | +143.5% | +17.5% | +126.6% | +496.5% | +10.4% | +143.6% | -18.6% | |
| EV / EBIT | 6.89 | — | 1.67 | 1.86 | 1.79 | 3.43 | 5.66 | — | 13.65 | 27.77 | — | 7.65 | 6.03 | 19.34 | 9.72 | 10.99 | 8.00 | 15.04 | 5.06 | 11.21 | 6.54 |
| — | — | -70.5% | — | -86.9% | -87.6% | — | — | +126.4% | +43.6% | — | -30.4% | -24.6% | +28.6% | +92.0% | -1.9% | +22.3% | +374.5% | +15.2% | +143.6% | +46.2% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.3% | 79.5% | 75.8% | 77.4% | 64.1% | 76.1% | 89.4% | 90.0% | 92.2% | 88.8% | 82.2% | 85.8% | 84.7% | 84.7% | 70.4% | 70.0% | 80.5% | 77.1% | 100.0% | 100.0% | 100.0% |
| — | +4.5% | -15.3% | -14.0% | -30.5% | -14.4% | +8.8% | +4.9% | +8.8% | +4.9% | +16.8% | +22.7% | +5.2% | +9.8% | -29.6% | -30.0% | -19.5% | -22.9% | +0.0% | +0.1% | +0.2% | |
| Operating Margin | 38.5% | 39.7% | 42.5% | 38.9% | 33.0% | 32.1% | -48.6% | -46.7% | 47.0% | 55.6% | 52.9% | 33.3% | 43.7% | 36.2% | 22.8% | 27.6% | 46.9% | 18.3% | 76.3% | 86.3% | 97.1% |
| — | +23.8% | +187.5% | +183.3% | -29.7% | -42.3% | -191.9% | -240.4% | +7.5% | +53.7% | +131.7% | +20.5% | -6.7% | +97.4% | -70.1% | -68.0% | -51.7% | -81.0% | -20.3% | -7.1% | +3.6% | |
| Net Margin | 63.8% | -69.6% | -69.8% | 190.4% | 139.1% | 83.4% | 63.5% | -52.6% | 22.1% | 1.4% | -33.6% | 47.1% | 71.7% | 122.0% | 1.6% | 45.7% | -103.8% | 394.8% | 0.9% | 17.5% | 9.6% |
| — | -183.5% | -209.8% | +462.3% | +527.9% | +6054.3% | +289.2% | -211.5% | -69.1% | -98.9% | -2223.5% | +3.3% | +169.0% | -69.1% | +82.1% | +160.7% | -1180.6% | +433.3% | -99.0% | -84.1% | -83.9% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 29.1% | -6.2% | -6.5% | 14.8% | 15.0% | 10.4% | 9.4% | -7.0% | 3.0% | 0.2% | -5.1% | 5.3% | 9.4% | 13.9% | 0.2% | 6.2% | -11.3% | 44.0% | 0.2% | 2.9% | 2.0% |
| — | -159.8% | -169.3% | +313.2% | +402.9% | +5631.4% | +284.6% | -231.4% | -68.3% | -98.7% | -2309.6% | -14.3% | +183.5% | -68.5% | +36.5% | +111.4% | -656.8% | +169.0% | -99.0% | -79.7% | -78.5% | |
| ROA | 18.5% | -4.6% | -4.7% | 10.7% | 10.7% | 6.5% | 4.9% | -3.6% | 1.6% | 0.1% | -2.8% | 2.9% | 5.1% | 7.1% | 0.1% | 3.0% | -5.3% | 21.5% | 0.1% | 1.6% | 1.1% |
| — | -170.1% | -195.8% | +394.8% | +567.3% | +6487.9% | +276.8% | -225.3% | -68.3% | -98.6% | -2543.5% | -1.5% | +194.8% | -67.0% | +36.2% | +90.4% | -568.0% | +149.2% | -99.1% | -82.8% | -79.7% | |
| ROIC | 14.2% | 3.6% | 3.8% | 2.9% | 3.3% | 3.2% | -4.7% | -3.8% | 3.8% | 4.2% | 4.4% | 2.0% | 3.1% | 2.1% | 1.6% | 1.9% | 2.7% | 1.1% | 7.3% | 7.3% | 10.7% |
| — | +12.6% | +180.6% | +175.9% | -12.3% | -24.8% | -208.0% | -289.2% | +23.8% | +100.9% | +167.6% | +8.1% | +13.4% | +95.4% | -77.5% | -74.2% | -74.6% | -88.6% | -22.6% | -5.2% | -0.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.23 | 0.24 | 0.22 | 0.25 | 0.23 | 0.32 | 0.63 | 0.70 | 0.65 | 0.67 | 0.68 | 0.64 | 0.67 | 0.72 | 0.81 | 0.80 | 0.96 | 0.85 | 0.96 | 0.98 | 0.75 |
| — | -25.9% | -65.3% | -64.6% | -64.9% | -52.5% | -6.9% | +9.2% | -1.9% | -5.7% | -16.1% | -20.0% | -30.8% | -15.6% | -15.9% | -18.8% | +28.1% | +6.3% | -3.0% | +76.6% | +18.3% | |
| Debt / EBITDA | 1.32 | 5.15 | 4.42 | 6.88 | 5.48 | 7.85 | — | — | 9.09 | 7.55 | 7.37 | 13.93 | 10.20 | 14.55 | 19.10 | 17.97 | 15.57 | 39.61 | 6.30 | 11.37 | 3.66 |
| — | -34.3% | — | — | -39.7% | +3.9% | — | — | -10.9% | -48.1% | -61.4% | -22.4% | -34.5% | -63.3% | +203.0% | +58.0% | +325.9% | +889.5% | +56.0% | +133.1% | -19.6% | |
| Current Ratio | 14.64 | 15.44 | 16.01 | 21.13 | 14.64 | 14.12 | 2.64 | 2.48 | 2.35 | 1.79 | 12.70 | 10.42 | 9.03 | 8.43 | 8.21 | 7.77 | 3.29 | 2.77 | 3.18 | 2.91 | 54.02 |
| — | +9.3% | +505.5% | +752.4% | +523.5% | +688.8% | -79.2% | -76.2% | -74.0% | -78.8% | +54.7% | +34.1% | +174.7% | +203.9% | +158.3% | +167.1% | -93.9% | -96.3% | -88.5% | -97.0% | -3.5% | |
| Quick Ratio | 13.85 | 14.58 | 15.18 | 20.07 | 13.85 | 13.33 | 2.44 | 2.30 | 2.21 | 1.64 | 11.40 | 9.17 | 7.96 | 7.31 | 7.02 | 6.47 | 2.87 | 2.34 | 3.15 | 2.91 | 54.02 |
| — | +9.4% | +520.9% | +771.7% | +528.1% | +714.2% | -78.6% | -74.9% | -72.3% | -77.6% | +62.4% | +41.7% | +177.1% | +212.1% | +123.1% | +122.4% | -94.7% | -96.9% | -88.6% | -97.0% | -3.5% | |
| Interest Coverage | 20.57 | -16.84 | 37.33 | 42.14 | 59.94 | 25.36 | 16.57 | -7.19 | 6.20 | 2.18 | -5.77 | 8.71 | 11.28 | 4.08 | 6.51 | 6.75 | 9.13 | 4.42 | 22.59 | 15.86 | 12.67 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying INVA stock.
Innoviva, Inc.'s current P/E is 7.1x. The average P/E over the last 2 quarters is 2.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Innoviva, Inc.'s current operating margin is 38.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Innoviva, Inc.'s business trajectory between earnings reports.